Literature DB >> 9007511

Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain.

L McCoy1, C Cox, E K Richfield.   

Abstract

We assessed the effects of chronic (21 day) administration of antipsychotic drugs on the density of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor in rat brain. We used two typical antipsychotic drugs, haloperidol and pimozide, and two atypical antipsychotic drugs, risperidone and clozapine. Antipsychotic drugs as a group significantly elevated the density of the AMPA receptor measured with an AMPA receptor agonist ([3H]AMPA), but not with an AMPA receptor antagonist, 6-cyano-7-nitro-quinoxaline-2,3-dione ([3H]CNQX). In all regions studied, the magnitude of the increase seen with chronic typical antipsychotic drugs was significantly greater than that seen with chronic atypical antipsychotic drugs. In frontal cortex and striatum, typical antipsychotics but not atypical antipsychotics elevated AMPA receptor binding over control. These findings suggest that antipsychotic drugs alter the agonist affinity of the AMPA receptor without altering the number of AMPA receptors. Typical antipsychotic drugs may be more potent in this effect than atypical antipsychotic drugs, especially in critical corticostriatal circuits.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9007511     DOI: 10.1016/s0014-2999(96)00910-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine.

Authors:  Chen Zhang; Ming Li
Journal:  Behav Pharmacol       Date:  2012-02       Impact factor: 2.293

Review 2.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

3.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

4.  Effects of risperidone on glutamate receptor subtypes in developing rat brain.

Authors:  Yong Kee Choi; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2008-10-09       Impact factor: 4.600

5.  Long-term effects of JL 13, a potential atypical antipsychotic, on ionotropic glutamate receptors.

Authors:  Frank I Tarazi; Taylor Moran-Gates; Matthew P Gardner; Amaury Graulich; Cédric Lamy; Jean-François Liégeois
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 2.866

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.